| | Catalent Opens New Full-Service Clinical Supply Facility in Shiga, Japan |
|
| The 6,000 square-meter-site will provide flexible clinical supply solutions, serving both local and global biotech and pharmaceutical companies. The facility, one of the largest of its kind in Japan, will play an important role in Catalent’s expanding Asia-Pacific network, working alongside two sites in China and one in Singapore to ensure customers’ clinical trials are well-served across the region. |
|
| | | Announcing Start of Long-Term Partnership with Phathom Pharmaceuticals |
|
| Catalent and Phathom Pharmaceuticals have signed a commercial supply agreement for Phathom’s lead compound, vonoprazan, which is a novel, orally active-potassium competitive acid blocker (P-CAB). As it works toward regulatory review, Phathom will leverage Catalent’s extensive capabilities and history of supporting successful product launches at its Winchester, Kentucky, facility. | | Find out More | Catalent Completes Acquisition of Bettera, a Leading Gummies Manufacturer |
|
| Catalent, Inc., has completed the acquisition of Bettera Holdings, LLC, a major manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements, complementing and accelerating the growth of Catalent’s global softgel and oral dose formulation and manufacturing business to provide consumer health innovators with unrivalled choice, formulation expertise, and high-quality, scalable manufacturing solutions to help bring new products to market. | | Learn more about gummy delivery technologies |
|
| | | Catalent Expert Discusses Challenges of Controlled Release Formulations Ron Vladyka, Director of Scientific Services, Oral and Specialty Delivery at Catalent joins other industry experts to discuss the challenges of controlled release formulations in Pharmaceutical Technology. |
|
| | | | | Investing in PBPK – Catalent Experts Featured in Pharmaceutical Outsourcing
Published in Pharmaceutical Outsourcing, Anders Lindahl, Ph.D. and Jan Neelissen, Ph.D. discuss the ways investing in PBPK early in the development process can help minimize development risk. | | Read the Article | | |
|
| Raman Spectroscopy Discussed by Catalent Expert in Contract Pharma
Raman spectroscopy helps ensure quality along the pharma supply chain of materials—from incoming raw materials through to finished product. Read the article, published in Contract Pharma, by Jacques Ledru, Head of Characterization at Catalent’s facility in Nottingham, U.K. | | Read the Article | | | Catalent Adding Hundreds of Jobs in Bloomington, Indiana Inside Indiana Business reports on how Catalent is responding to growing demand at the Bloomington site. | | Read the Article |
|
| Upcoming Events: Join Our Experts to Hear the Latest on Technology Development Programs |
|
| | | | | | | A Catalyst in Drug Development |
|
| Lun Xin, M.Sc. Senior Formulation Development Scientist |
|
| In his role at Catalent, Mr. Xin focuses on establishing formulation development and manufacturing capabilities for mRNA-LNP delivery platforms. He collaborates with Catalent’s global data science team to couple the high-throughput formulation development lab with automated data and reporting workflow. He has extensive knowledge in pharmacokinetics/pharmacodynamics, and non-invasive drug delivery as applied to biologics. Learn what drives his commitment to research, and access his works on developing high-throughput formulations, fluorescence microscopy detection and more. |
|
|
|
| | | | | | | | Biologics Development and Manufacturing
| | | Cell and Gene Therapies - In this 360° virtual tour, explore Catalent’s Harmans/BWI-1 clinical through commercial manufacturing facility for gene therapies. The state-of-the-art, FDA-licensed facility, at approximately 200,000 sq. ft., houses 10 CGMP manufacturing suites, including fill/finish, and contains central services labs, testing labs, and acts as our central warehouse and supply chain hub for Catalent Gene Therapy.
|
|
| | | Oral Development and Manufacturing - In this 360° virtual tour, explore Strathroy, Ontario, one of two sites located in Canada offering softgel development and manufacturing capabilities for the Pharmaceutical and Consumer Health industries.
- Catalent’s Boston facility provides manufacturing and development services for inhaled powders. The site features a top-tier vendor set for capsule filling and blister packaging lines as well as spray dryers up to PSD-7 scale, the largest size for GMP pharmaceutical use in North America. With expertise in commercial launch and scale-up, the Boston site is a center-of-excellence for tech transfer projects.
|
| We are the Catalyst for your success. Join us! |
|
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana; Madison, Wisconsin; Harmans, Maryland; Kansas City, Missouri; and across Europe.
Visit www.catalent.com/careers for more information. |
|
| | |
|
Every brand has a challenge. We have a solution.
|
|
| | | or call +1 877 891 9609 to speak with one of our experts today! |
|
| | |
|
To unsubscribe or manage your subscriptions, please click here. For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at [email protected], or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2021, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
